Baseline characteristics and feasibility of clinical outcome measures in <scp>CDKL5</scp> deficiency disorder: The <scp>CANDID</scp> observational study

The scales in the CANDID study capture disease-related deficits and phenotype variability in CDD. Floor effects in subdomains aligned with disease severity. The GMFM-88 lacks granularity, and its operational limitations make it unsuitable for CDD trials. Baseline analyses demonstrate the feasibility and potential value of most selected scales, supporting their use in optimizing trial design and endpoint selection for future CDD clinical trials.

Authors

Institutions

Publication Details

Journal
Epilepsia
Published
2026-01-13
DOI
https://doi.org/10.1002/epi.70095
Primary Topic
Genetics and Neurodevelopmental Disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Baseline characteristics and feasibility of clinical outcome measures in CDKL5 deficiency disorder: The CANDID observational study

Tricia Cimms, Kristina Lindsten, Alison Skrinar, Xavier Liogier D’ardhuy et al.
Epilepsia
Genetics and Neurodevelopmental Disorders
article

Baseline characteristics and feasibility of clinical outcome measures in CDKL5 deficiency disorder: The CANDID observational study

Tricia Cimms, Kristina Lindsten, Alison Skrinar, Xavier Liogier D’ardhuy, Marco Rizzo, Orrin Devinsky, Ana Mingorance, Peter St. Wecker, CANDID Partners
article en

Abstract

The scales in the CANDID study capture disease-related deficits and phenotype variability in CDD. Floor effects in subdomains aligned with disease severity. The GMFM-88 lacks granularity, and its operational limitations make it unsuitable for CDD trials. Baseline analyses demonstrate the feasibility and potential value of most selected scales, supporting their use in optimizing trial design and endpoint selection for future CDD clinical trials.

Epilepsia
Biogen (United States) (US), North Carolina Institute of Medicine (US), Ultragenyx Pharmaceutical (United States) (US), Redwood Pharma (Sweden) (SE), Loulou Foundation (GB), New York University (US)
Openalex Percentile: Top 90%
Genetics and Neurodevelopmental Disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.